Floatz logo

AXUMIN

Ovarian Carcinoma

Bital Savir-BaruchSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

236 Active assets in the Ovarian Carcinoma cohort.

Asset / SponsorPhaseRating
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Trabectedin
AGO Research GmbH
Phase 4BBB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
Olaparib
Imunon
Phase 4BB
Carboplatin
University of Washington
Phase 3BB

View all 50 →

Same molecule, other indications

AXUMIN is also rated in:

metastatic prostate carcinomaActive
BBB
Indicative · Phase 4
73 / 100
View asset →
prostate carcinomaActive
BB
Indicative · Phase 3
66 / 100
View asset →
prostate cancerActive
B
Indicative · Phase 4
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →